封面
市場調查報告書
商品編碼
1378699

阿拉吉爾症候群治療藥物市場:按藥物、配銷通路和地區

Alagille Syndrome Treatment Market, By Drug, By Distribution Channel, By Geography

出版日期: | 出版商: Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2023 年,全球 Alagille症候群治療市場將達到 8,890 萬美元,預計在預測期內(2023-2030 年)年複合成長率為 6.6%。

報告範圍 報告詳情
基準年 2022年 2023年市場規模 8890萬美元
實績資料 2018-2021 預測期 2023-2030
預測期年複合成長率 6.60% 2030年市場規模預測 1.387 億美元
圖 1. Alagille症候群治療藥物的全球市場佔有率(%),按藥物分類,2023 年
阿拉吉爾症候群治療市場-IMG1

阿拉吉爾症候群是一種遺傳性疾病,會影響身體的不同部位,包括肝臟、心臟、眼睛、臉部、骨骼、血管和腎臟。阿拉吉爾症候群患者肝臟中的小膽管數量少於正常數量。膽管將來自肝臟的膽汁儲存在膽囊中,並將其運送到小腸的第一部分(也稱為十二指腸)以進行消化。當膽管較少時,從肝臟流出的膽汁就會減少。這種情況稱為膽汁淤積。如果膽汁在肝臟中積聚,就會導致肝損傷。因此,在預測期內,用於治療Alagille症候群的新藥的引入預計將推動全球Alagille症候群治療藥物市場的成長。

市場動態

製藥業的主要參與者正致力於開發具有不同方法和平台的新藥來治療 Alagille症候群。因此,將此類先進產品引入市場預計將在預測期內推動全球 Alagille症候群治療藥物市場的成長。例如,2023年6月13日,全球生物製藥公司易普森製藥公司宣布,美國食品藥物管理局(FDA)已批准用於治療12個月及以上阿拉吉爾症候群(ALGS)患者的膽汁淤積性搔癢症。Balllvay(odevixibat) 作為藥物的核准。

本研究的主要特點

  • 本報告對全球Alagille症候群治療藥物市場進行了詳細分析,並提出了以2022年為基準年的預測期(2023-2030)的市場規模和復合年度(年複合成長率)。它還強調了各個細分市場的潛在收益成長機會,並為該市場說明了一系列有吸引力的投資提案。
  • 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
  • 根據公司亮點、產品系列、主要亮點、績效和策略等參數對全球阿拉吉爾症候群治療藥物市場的主要參與者進行了分析。
  • 本研究涵蓋的主要企業包括 Teva Pharmaceutical Industries Ltd.、AbbVie, Inc.、Glenmark Pharmaceuticals Limited、Par Pharmaceuticals, Inc.、Mylan Pharmaceuticals, Inc.、Sanofi SA、Mylan NV、Novartis International AG、Akorn, Inc.、Albireo Pharma, Inc.、Mirum Pharmaceuticals、Ipsen Pharma、CANbridge Pharmaceuticals, Inc. 等。
  • 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場經營團隊和行銷策略做出明智的資訊。
  • 全球阿拉吉爾症候群治療藥物市場報告迎合了該行業的各個相關人員,如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 相關人員可以透過用於分析全球阿拉吉爾症候群治療藥物市場的各種策略矩陣來促進他們的決策。

目錄

第1章 研究目的與前提

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要

第3章 市場動態、法規及趨勢分析

    • 市場動態
  • 促進因素
  • 抑制因素
  • 市場機會
    • 影響分析
    • 最近測試啟動
    • 流行病學
    • 合併、收購和合作
    • 法規場景
    • 診斷和治療概述
    • 主要進展
    • PEST分析

第4章 全球Alagille症候群治療藥物市場 – COVID-19 的影響分析

    • 經濟影響
    • COVID-19 的流行病學
    • 對需求和供給的影響

第5章 全球Alagille症候群治療藥物市場,依藥物分類,2018-2030 年

  • 熊去氧膽酸
  • 消膽胺
  • 利福平
  • 後期管線藥物
  • 其他

第6章 全球Alagille症候群治療藥物市場,依配銷通路,2018-2030 年

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章 2018-2030年全球Alagille症候群治療藥物市場(按地區)

  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中東
  • GCC
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第8章 競爭形勢

  • 公司簡介
    • Teva Pharmaceutical Industries Ltd.
    • AbbVie, Inc.
    • Glenmark Pharmaceuticals Limited
    • Par Pharmaceuticals, Inc.
    • Mylan Pharmaceuticals, Inc.
    • Sanofi SA
    • Mylan NV
    • Novartis International AG
    • Akorn, Inc.
    • Albireo Pharma, Inc.
    • Mirum Pharmaceuticals
    • Ipsen Pharma
    • CANbridge Pharmaceuticals, Inc.

第9章 章節

  • 參考
  • 調查方法
簡介目錄
Product Code: CMI4398

The global alagille syndrome treatment market is estimated to be valued at US$ 88.9 Million in 2023 and is expected to exhibit a CAGR of 6.6% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 88.9 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 6.60% 2030 Value Projection: US$ 138.7 Mn
Figure 1. Global Alagille Syndrome Treatment Market Share (%), By Drug, 2023
Alagille Syndrome Treatment Market - IMG1

Alagille syndrome is a genetic disorder that may affect many different parts of the body including the liver, heart, eyes, face, skeleton, blood vessels, and kidneys. A person with Alagille syndrome has fewer than the normal number of small bile ducts inside the liver. Bile ducts carry bile from the liver to the gallbladder for storage and then to the first part of the small intestine, also called the duodenum, for use in digestion. With fewer small bile ducts, less bile flows out of the liver. This condition is called cholestasis. As bile builds up in the liver, it may cause liver damage. Thus, the introduction of new drugs for the treatment of alagille syndrome in the market is expected to drive the growth of the global alagille syndrome treatment market over the forecast period.

Market Dynamics

The key players in the pharmaceutical industry are focusing on the development of new drugs with different approaches and platforms for the treatment of Alagille syndrome. Thus, the introduction of such advanced products in the market is expected to drive the growth of the global alagille syndrome treatment market over the forecast period. For instance, on June 13, 2023, Ipsen Pharma, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved Bylvay (odevixibat) for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille Syndrome (ALGS).

Key features of the study:

  • This report provides an in-depth analysis of the global alagille syndrome treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year. It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global alagille syndrome treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • The key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Glenmark Pharmaceuticals Limited, Par Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Sanofi S.A., Mylan N.V., Novartis International AG, Akorn, Inc., Albireo Pharma, Inc., Mirum Pharmaceuticals, Ipsen Pharma, and CANbridge Pharmaceuticals, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global alagille syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global alagille syndrome treatment market

Alagille Syndrome Treatment Market Detailed Segmentation:

  • By Drug:
    • Ursodeoxycholic Acid
    • Cholestyramine
    • Rifampicin
    • Late Stage Pipeline Drugs
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • Middle East & Africa
  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.
    • AbbVie, Inc.
    • Glenmark Pharmaceuticals Limited
    • Par Pharmaceuticals, Inc.
    • Mylan Pharmaceuticals, Inc.
    • Sanofi S.A.
    • Mylan N.V.
    • Novartis International AG
    • Akorn, Inc.
    • Albireo Pharma, Inc.
    • Mirum Pharmaceuticals
    • Ipsen Pharma
    • CANbridge Pharmaceuticals, Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
    • Impact Analysis
    • Recent Test Launches
    • Epidemiology
    • Merger, Acquisition, and Collaborations
    • Regulatory Scenario
    • Diagnosis & Treatment Overview
    • Key Developments
    • PEST Analysis

4. Global Alagille Syndrome Treatment Market - COVID-19 Impact Analysis

    • Economic Impact
    • COVID-19 Epidemiology
    • Impact on Supply and Demand

5. Global Alagille Syndrome Treatment Market, By Drug, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Ursodeoxycholic Acid
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Cholestyramine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Rifampicin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Late Stage Pipeline Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends

6. Global Alagille Syndrome Treatment Market, By Distribution Channel, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends

7. Global Alagille Syndrome Treatment Market, By Region, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018-2030, (US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

8. Competitive Landscape

  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • AbbVie, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Glenmark Pharmaceuticals Limited
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Par Pharmaceuticals, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Mylan Pharmaceuticals, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Sanofi S.A.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Mylan N.V.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Novartis International AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Akorn, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Albireo Pharma, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Mirum Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Ipsen Pharma
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • CANbridge Pharmaceuticals, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact